Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is a commercial-stage biotechnology company with a deep pipeline in multiple therapeutic areas. Its lead product, KIMMTRAK, has demonstrated strong sales growth and market penetration, and its Phase 3 trial data has shown significant overall survival benefit in treating HLA-A*02:01-positive metastatic uveal melanoma (mUM). The company also has a robust pipeline with multiple drug candidates targeting various oncology, infectious, and autoimmune diseases, with upcoming late-stage readouts that could further strengthen its position in the biotech industry. The company's strong financials and potential for future growth make it a promising investment opportunity.

Bears say

Immunocore Holdings is a commercial-stage biotechnology company with a pipeline of drug candidates targeting multiple therapeutic areas including oncology, infectious disease, and autoimmune disease. While their lead product KIMMTRAK has shown success in treating uveal melanoma, the company's reliance on this small patient pool could lead to increased rebates and discounts on a potential label expansion. Additionally, the regulatory landscape for TCR-based therapies is still relatively unknown, which could impact the development and approval of Immunocore's drugs in the future. Overall, these factors contribute to a negative outlook for the company's stock.

Immunocore Holdings (IMCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 6 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.